Cargando…

Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

SIMPLE SUMMARY: Effective anti-infective strategies are of crucial importance in patients with multiple myeloma undergoing high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT). We compare, for the first time, antibiotic prophylaxis versus granulocyte-colony stimulating facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Eva-Maria, Sauer, Sandra, Klein, Sabrina, Tichy, Diana, Benner, Axel, Bertsch, Uta, Brandt, Juliane, Kimmich, Christoph, Goldschmidt, Hartmut, Müller-Tidow, Carsten, Jordan, Karin, Giesen, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303829/ https://www.ncbi.nlm.nih.gov/pubmed/34298654 http://dx.doi.org/10.3390/cancers13143439

Ejemplares similares

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

Quality of Online Information on Multiple Myeloma Available for Laypersons
por: Staemmler, Henrike, et al.
Publicado: (2022)

Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma
por: Neuendorff, Nina Rosa, et al.
Publicado: (2023)

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
por: Cox, J E, et al.
Publicado: (2014)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma
por: Ding, Xinjing, et al.
Publicado: (2022)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients
por: Sauer, Sandra, et al.
Publicado: (2023)

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
por: Lehners, Nicola, et al.
Publicado: (2017)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Cell-based immunotherapy approaches for multiple myeloma
por: Kriegsmann, Katharina, et al.
Publicado: (2018)

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
por: GroΔ, Jonathan P., et al.
Publicado: (2017)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
por: Aslam, Saad, et al.
Publicado: (2023)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?()
por: Vigorito, Afonso Celso
Publicado: (2016)

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
por: Lisenko, Katharina, et al.
Publicado: (2017)

Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Eplin, Dwight D., et al.
Publicado: (2019)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
por: Miller, Kevin Charles, et al.
Publicado: (2022)

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
por: Cooper, Katy L, et al.
Publicado: (2011)

Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
por: Link, Hartmut
Publicado: (2022)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
por: Kauer, Joseph, et al.
Publicado: (2023)

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
por: Leleu, Xavier, et al.
Publicado: (2017)

Risk factors for neutropenic fever in non- Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
por: Kim, Yu Ri, et al.
Publicado: (2021)

Effects of primary granulocyte-colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
por: Hapakova, Nikola, et al.
Publicado: (2022)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
por: Jung, Jae Hyup, et al.
Publicado: (2020)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

The importance of the granulocyte-colony stimulating factor in oncology
por: CETEAN, SÎNZIANA, et al.
Publicado: (2015)

Granulocyte Colony-stimulating Factor-associated Aortitis
por: Nishioka, Hiroaki, et al.
Publicado: (2023)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n2ch0oe5b5jp85sjaupq8pgb7s